New cell therapy tested for Tough-to-Treat blood cancer

NCT ID NCT07294625

First seen Jan 06, 2026 · Last updated Apr 05, 2026 · Updated 13 times

Summary

This early-stage study is testing a new cell therapy called LVIVO-TaVec200 for patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to find a safe dose, see how the body handles the treatment, and check for early signs that it might help control the cancer. About 36 participants will be followed for roughly two years to monitor their health and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

    Contact

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

  • The Affiliated Hospital of XUZHOU Medical University

    NOT_YET_RECRUITING

    Xuzhou, Jiangsu, China

    Contact

  • The First Affiliated Hospital with Nanjing Medical University

    RECRUITING

    Nanjing, Jiangsu, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    NOT_YET_RECRUITING

    Xi’an, Shanxi, China

    Contact

Conditions

Explore the condition pages connected to this study.